Polymeric cyclosporine-A nanoparticles for ocular application

Journal of Biomedical Nanotechnology

Volumn 7, Issue 5, 2011, Pages 714-723

  Başaran, Ebru ^a   Demirel, Müzeyyen ^a   Sirmagül, Başar ^b   Yazan, Yasemin ^a  

^a ANADOLU UNIVERSITY   (Turkey)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Cationic nanoparticles; Cyclosporine A; Eudragit RS 100; Ocular application

Indexed keywords

CATIONIC NANOPARTICLES; CYCLOSPORINE A; EUDRAGIT; EXTENDED RELEASE; IMMUNE ASSAY; IN-VITRO; IN-VIVO; PHYSICO-CHEMICAL CHARACTERIZATION; POSITIVELY CHARGED; RESIDENCE TIME; STORAGE PERIODS; TIME INTERVAL;

BIOTECHNOLOGY; NANOTECHNOLOGY;

NANOPARTICLES;

CYCLOSPORIN A; EUDRAGIT RS; EUDRAGIT RS 100 NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; ACRYLIC ACID RESIN; CYCLOSPORIN; POLYMER;

AQUEOUS HUMOR; ARTICLE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; ENZYME IMMUNOASSAY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; SHEEP; VITREOUS BODY; ANIMAL; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFECT; EYE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PH; STATIC ELECTRICITY; ULTRASTRUCTURE; X RAY DIFFRACTION;

ACRYLIC RESINS; ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; EYE; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE SPECTROSCOPY; NANOPARTICLES; PARTICLE SIZE; POLYMERS; SHEEP; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; X-RAY DIFFRACTION;

EID: 84856022970     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2011.1325     Document Type: Article

References (41)

1. C.-L. Lee, P.-P. Jiang, W.-H. Sit, and J. M.-F. Wan, Proteome of human T lymphocytes with treatment of cyclosporine and polysaccharopeptide: Analysis of significant proteins that manipulate T cells proliferation and immunosuppression. Int. Immunopharm. 7, 1311 (2007).
2. S. Tamilvanan, K. Khoury, D. Gilhar, and S. Benita, Ocular delivery of cyclosporin A I. Design and characterization of cyclosporin A-loaded positively-charged submicron emulsion, S.T.P Pharm. Sci. 11, 421 (2001).
3. E. Mannermaa, K.-S. Vellonen, and A. Urtti, Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev. 58, 1136 (2006).
4. E. Eljarrat-Binstock, F. Orucov, Y. Aldouby, J. Frucht-Pery, and A. J. Domb, Charged nanoparticles delivery to the eye using hydrogel iontophoresis. J. Control. Rel. 126, 156 (2008).
5. R. C. Nagarwal, S. Kant, P. N. Singh, P. Maiti, and J. K. Pandit, Polymeric nanoparticulate system: A Potential approach for ocular drug delivery. J. Control. Rel. 136, 2 (2009).
6. R. Pignatello, C. Bucolo, P. Ferrara, A. Maltese, A. Puelo, and G. Puglisi, Eudragit® RS 100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci. 16, 53 (2002).
7. S. M. Agnihotri and P. R. Vavia, Diclofenac-loaded biopolymeric nanosuspensions for Ophthalmic application. Nanomedicine: Nanotechnology, Biology, and Medicine 5, 90 (2009).
8. E. Başaran, M. Demirel, B. Sirmagül, and B. Y. Yazan, Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J. Microencapsul. 27, 37 (2010).
9. F. Castelli, C. Messina, M. G. Sarpietro, R. Pignatello, and G. Puglisi, Eudragit as controlled release system for anti-inflammatory drugs A comparison between DSC and dialysis experiments. Thermochimica Acta 400, 227 (2003).
10. A. M. De Campos, A. Sánchez, and M. J. Alonso, Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224, 159 (2001).
11. J. Shen, Y. Deng, X. Jin, Q. Ping, Z. Su, and L. Li, Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int. J. Pharm. 402, 248 (2010).
12. P. Aksungur, M. Demirbilek, E. B. Denkbaş, J. Vandervoort, A. Ludwig, and N. Ünlü, Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J. Control. Rel. 151, 286 (2011).
13. M. Abdulrazik, S. Tamilvanan, K. Khoury, S. Benita, Ocular delivery of cyclosporin A II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. S.T.P. Pharm. Sci. 11, 427 (2001).
14. S. Tamilvanan and S. Benita, The Potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur. J. Pharm. Biopharm. 58, 357 (2004).
15. R. Pignatello, M. Ferro, G. De Guidi, G. Salemi, S. Guccione, M. Geppi, M. A. Vandelli, C. Forte, and G. Puglisi, Preparation, characterisation and photosensitivity studies of solid dispersions of diflunisal and Eudragit® RS100 and RL® 100. Int. J. Pharm. 218, 27 (2001).
16. R. I. Moustafine, T. V. Kabanova, V. A. Kemenova, and G. Van den Mooter, Characteristics of interpolyelectrolyte complexes of Eudragit E 100 with Eudragit L 100. J. Control. Rel. 103, 191 (2005).
17. K. Dillen, J. Vandervoort, G. Van den Mooter, and A. Ludwig, Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int. J. Pharm. 314, 72 (2006).
18. A. Lopedota, A. Trapani, A. Cutrignelli, L. Chiarantini, E. Pantucci, R. Curci, E. Manuali, and G. Trapani, The use of Eudragit® RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. Eur. J. Pharm. Biopharm. 72, 509 (2009).
19. K. Letchford, H. Burt, A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: Micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 65, 259 (2007).
20. I. K. Reddy and M. G. Ganesan, Ocular therapeutics and drug delivery: An overview, Ocular Therapeutics and Drug Delivery, A Multi- Disciplinary Approach, edited by I. K. Reddy, Technomic Publishing Company Inc., Lancaster (1996), p. 3.
21. K. Manjunath, J. S. Reddy, and V. Venkateswarlu, Solid lipid nanoparticles as drug delivery systems. Methods Find. Exp. Clin. Pharmacol. 27, 127 (2005).
22. R. H. Müller and S. Heinemann, Fat emulsions for parenteral nutrition II: Characterisation and physical long-term stability of lipo-fundin MCT/LCT. Clin. Nutr. 12, 298 (1993).
23. R. H. Müller, S. A. Runge, V. Ravelli, W. Mehnert, A. F. Thünemann, and E. B. Souto, Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int. J. Pharm. 317, 82 (2006).
24. H. Hägerstrom, M. Paulsson, and K. Edsman, Evaluation of mucoadhesion for two polyelectrolyte gels in simulated physiological conditions using a rheological method. Eur. J. Pharm. Sci. 9, 301 (2000).
25. A. Z. Gürsoy and Oküler sistemler, Kontrollü Salim Sistemleri, edited by A. Z. Gürsoy, Elma Bilgisayar Basim ve Ambalaj San. Tic.Ltd. Şti., Istanbul (2002), pp. 197-217.
26. J. Shen, Y. Deng, X. Jin, Q. Ping, Z. Su, and L. Li, Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int. J. Pharm. 402, 248 (2010).
27. G. Choc, Cyclosporine: Pharmacology, Cyclosporine; Clinical Application in Autoimmune Diseases, edited by D. E. Yocum, Harcourt Health Communications, Philadelphia (2000), pp. 15-29.
28. V. Hirunpanich, E. Sugiyama, and H. Sato, Ethyl docosahexaenoate decreased Neoral® absorption due to particle size enlargement. Int. J. Pharm. 361, 251 (2008).
29. CEDIA® Cyclosporine PLUS Assay Specification Sheet, Microgenics Corporation Fremont, USA (2006).
30. J. Araújo, E. Gonzalez, M. A. Egea, M. L. Garcia, and E. B. Souto, Nanomedicines for ocular NSAIDs: Safety on drug delivery. Nanomedicine: NBM 5, 394 (2009).
31. A. Trapani, V. Laquintana, N. Denora, A. Lopedota, A. Cutrignelli, M. Franco, G. Trapani, and G. Liso, Eudragit RS 100 microparticles containing 2-hydroxypropyl-cyclodextrin and glutathione: Physicochemical characterization, drug release and transport studies. Eur. J. Pharm. Sci. 30, 64 (2007).
32. J. Fujimori, Y. Yoshihashi, and E. Yo, Application of Eudragit RS to thermo-sensitive drug delivery systems II. Effect of temperature on drug permeability through membrane consisting of Eudragit RS/PEG400 blend polymers. J. Control. Rel. 102, 49 (2005).
33. S. Das, P. Suresh, and R. Desmukh, Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine: NBM 6, 318 (2010).
34. A. Kumari, S. K. Yadav, and S. C. Yadav, Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B 75, 118 (2010).
35. S. K. Motwani, S. Chopra, S. Talegaonkar, K. Kohli, F. J. Ahmad, and R. K. Khar, Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur. J. Pharm. Biopharm. 68, 513 (2008).
36. H. Gupta, M. Aqil, R. K. Khar, A. Ali, A. Bhatnagar, and G. Mittal, Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine:NBM 6, 324 (2010).
37. A. Ludwig, The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv. Rev. 57, 1595 (2005).
38. F. Lallemand, O. Felt-Baeyens, S. Rudaz, A. R. Hamel, F. Hubler, R. Wenger, M. Mutter, K. Besseghir, and R. Gurny, Conversion of cyclosporine A prodrugs in human tears versus rabbits tears. Eur. J. Pharm. Biopharm. 59, 51 (2005a).
39. F. Lallemand, P. Furrer, O. Felt-Baeyens, M. Gex-Fabry, J. M. Dumont, K. Besseghir, R. Gurny, A novel water-soluble cyclosporine A prodrug: Ocular tolerance and in vivo kinetics. Int. J. Pharm. 295, 7 (2005b).
40. F. Lallemand, O. Felt-Baeyens, K. Besseghir, F. Behar-Cohen, and R. Gurny, Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur. J. Pharm. Biopharm. 56, 307 (2003).
41. N. Ubrich, C. Schmidt, R. Bodmeier, M. Hoffman, and P. Maincent, Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. Int. J. Pharm. 288, 169 (2005).